Phytomixture with sedative effect

FIELD: medicine, pharmaceutics.

SUBSTANCE: invention relates to pharmaceutical industry, in particular to phytomixture with sedative effect. Phytomixture contains mixture of Leonurus cardiaca herb, hop cones, Origanum vulgare herb, and hawthorn fruit, taken in specified quantity.

EFFECT: claimed phytomixture possesses increased sedative effect, improved organoleptic properties, as well as reduced side effects.

3 cl, 3 ex

 

The invention relates to medical and food industry and can be used for cooking photonasty (herbal tea) sedative action, used when eating to prevent and relieve stress, anxiety, increased nervous excitability, insomnia, nervousness.

Since many modern psychotropic drugs (sedatives, anticonvulsant, antidepressant), which has lots of side effects, have limitations in their application, at the present time, the preferred biologically active additives to food containing natural biologically active substances that act as an alternative solution to the problem of prevention of primary manifestations asthenoneurotic States.

There is a huge amount of teas that are recommended to be used in the form of infusions and tinctures when asthenoneurotic States to reduce feelings of anxiety.

Some of them are used in the form of aqueous-ethanolic tinctures, containing, apart from the plants, Valerian. In the Patent of Russian Federation №2298413 described the remedy for the prevention and treatment of nervous diseases and diseases of the cardiovascular system. The product contains a mixture of alcoholic extracts of grass clover, motherwort, St. John's wort, lemon balm, Valerian, Heather, chicory roots, hawthorn hops. Similar recipes include Patents (applications) of the Russian Federation№2008128716, №2174005, №2185847, №2195951.

In the invention patent of Ukraine UA 49161 U, 26.04.2010 revealed treatment-and-prophylactic agent sedative, hypotensive action, containing the herb motherwort (15,0-25,0%), hop cones (10,0-20,0%), hawthorn (10,0-20,0%), marjoram (5,0-15,0%), the herb lemon balm (10,0-20,0%), root and rhizome of Valerian (5,0-15,0%), grass, dried flowers crimson (10,0-20,0%) and 70% aqueous-alcoholic solution. It should be noted that the term "dried flowers" translated from Ukrainian means everlasting.

However, all these means represent the spirit of the composition, of which you cannot prepare Supplements in the form of aqueous infusions for consumption during the meal in a long time. The presence of alcohol is a direct contraindication for daily 3-time use by the elderly and young children, and persons employed on work requiring special attention (drivers). Alcohol is associated with many therapeutic drugs, e.g., antibiotics and antihypertensives.

In all of these the present Valerian adverse effects with prolonged use. You may experience headache, dizziness, drowsiness, weakness (see A. T. Burbello, Shabrov A.V., p. P. Denisenko, Modern Medicine�funds, 2 nd edition, 2003, p. 562).

In addition, Valerian has a specific smell, which can reduce appetite and adversely affect the process of eating.

Prolonged use of the compositions according to the patent of Ukraine No. 49161, because of the presence of dried flowers crimson or immortelle, can lead to stagnation of bile in the liver. This herb is not recommended for those who suffer from hyperacidity in the stomach (see L. J. Sklyarevskiy, etc., Medicinal plants in everyday life, M.: Rosselkhozizdat, 1987, p. 207-208).

It should be borne in mind that the main consumers of sedative herbal complexes are elderly people usually suffer from high blood pressure and a tendency to thrombosis. Use them well-known composition can lead to these side effects.

The closest to the claimed invention is the herbal collection RF Patent for the invention №2150286 published 10.06.2000 that contains the herb of Leonurus cardiaca, hop cones of the ordinary and leaves of nettle in the following ratio of components, wt.%: herb of Leonurus cardiaca - 30,0; hop cones of the ordinary - 40,0; nettle leaves - 30,0.

The disadvantage of this collection is that it contains nettle, which is used for the inner and outer blood�oceniaj, promoting the clotting of blood due to the increased content of vitamin K (see Great Medical encyclopedia, 1998 ed. 3-3, vol. 12, page 520). These properties of nettle require careful application in elderly persons with increased blood clotting, persons suffering from varicose veins, thrombophlebitis.

In addition, this collection has insufficient sedative effect, and has a bitter taste "grassy" odor, perceived by the consumer as the smell of drugs, thereby reducing appetite.

The technical result of the claimed invention is to reduce side effects, increase the sedative effect, improving its organoleptic properties in the form of giving him a pleasant floral smell similar to the smell of flavored teas, and the extension of the range of sedatives, which allows the use of the claimed herbal collection in the dietary Supplement.

This technical result is achieved in that the known sedation herbal collection containing a mixture of dried and powdered herb of Leonurus cardiaca and hop cones, additionally contains the herb oregano and fruits of hawthorn, with the following ratio of components, wt.%:

Grass oregano 30-50
Herb Leonurus cardiaca20-40
Hawthorn10-30
Hop cones5-15

Single dose collection photonasty is 1-3.

The herbal collection is Packed in filter bags 1-3.

According to the definition given in article 1 of the Federal law of January 2, 2000 No. 29-FZ "About quality and safety of food products, biologically active supplements - natural (identical to natural) biologically active substances intended for use with food or introduction into the food composition.

It should be noted that for the production of biologically active food supplements in the form of herbal collection used the following raw materials permitted for use in food industry in accordance with the established procedure: the herb oregano, herb Leonurus cardiaca, hawthorn, hop cones. All raw materials must conform to hygienic requirements for safety and nutrition value of food products.

The components of the inventive herbal collection not only relate to the plants but also used as components of food that demonstrates their safety. It is well known the use of hop cones for conviction�allenii of bread and beer. In Russia before the advent of baking yeast breads used hop cones.

The oregano used for marinating vegetables (cucumbers, cabbage), it gives the pickles a fragrant, aromatic odor and taste (see Small Soviet encyclopedia, ed. by B. A. Vvedensky, ed. 3, 1959, p. 751). It can be added in syrups, marmalades, jellies, alcoholic and non-alcoholic drinks (see RF Patent №2529835, publ. 2003; No. 2528733, publ. 2013; No. 252033, publ. 2013). Oregano is added to the cheese (see RF Patent №2521664, publ. 2013). As vegetable seasonings can be added to salads, meat and other dishes (see RF Patent №2506823, publ. 2013). Oregano is used in cosmetics, from the Patent of Russian Federation №2157177, 1992

Hawthorn added to various pastries (see RF Patent №2341087, publ. 2008). The berries can be cooked many dishes, including sauces, marmalades, liqueurs (see RF Patent №2252776, publ. 2005; No. 2078520, publ. 1982; No. 2274005, 2003, the application for invention No. 2011116227, 2011). Hawthorn fruit also prepare food nutrient mixture (see Patent RF №2234224 C2, publ. 2004). Hawthorn is part of cosmetics, from the Patent of Russian Federation №2286140, publ. 2005

Motherwort herb has long been used in folk medicine. Drugs of Leonurus cardiaca have a sedative effect on the nervous and cardiovascular systems�s, slow the pace and increase the strength of the heartbeat, lowers blood pressure. Motherwort is indicated for insomnia, increased nervous excitability, i.e., in neurasthenia, hysteria, hypochondria, cardiovascular neurosis, angina (Great medical encyclopedia, edition 3, 1983, vol. 21, pp. 412-413).

Medicines hawthorn have a pronounced cardiotonic action: increase the contractile activity of the myocardium, the blood circulation in the coronary vessels of the heart and blood vessels of the brain, reduce the excitability of the Central nervous system, relieve arrhythmia phenomenon, several lower blood pressure. Shown in functional disorders of cardiac activity, the initial stages of hypertension, angina, insomnia, especially in people with heart disease (see Albakov A. J. Creation, technology research and standardization of multi-component herbal anti-stress action. Thesis K. Pharm. Sciences 2004, p. 25).

Origanum vulgare has a high antibacterial activity, has a sedative effect on the Central nervous system, normalizes the activity of the gastrointestinal tract. Drugs oregano is used for nervousness, hysteria, insomnia, atherosclerosis, with neurotic complaints in menopause, cramps of the stomach and intestines (see Big medicinskaya, edition 3, 1998, vol. 12, p. 518).

Drugs are aggregate fruits (cones) hops have a calming, diuretic, anti-inflammatory, antispasmodic and analgesic effect. Apply them with increased nervous excitability, insomnia, neurasthenia (see Great medical encyclopedia, 1998, 3rd edition, vol. 12, p. 525).

The herbal collection is prepared as follows.

For the preparation of herbal collection raw material is subjected to drying (if necessary) to the content of the mass fraction of moisture of 6-8%. The dried raw material is crushed to a particle size of 1.5 to 2 mm sieved, and then the components are mixed together.

It is preferable to package the herbal collection in filter bags (bags disposable brewing of filter paper). Can also be packaged loose in a soft and semi-rigid packs and boxes 30, 50, 75, 100, 125, 150, 200, 250 and 300 g, and artistically-decorated metal, glass, wood and other cinity and boxes that meet the requirements of normative-technical documentation, the net weight of the packaging unit from 0.05 to 1.0 kg.

The herbal collection has the following organoleptic characteristics.

A mixture of crushed vegetative raw materials are yellowish-green with pale yellow and brown inclusions, pleasant floral fragrance.

Appearance, color, aroma, and taste of water extract.

Infusion of transparent color from light brown �about brown. Pleasant taste that leaves no aftertaste. The aroma is delicate, fragrant. Recommendations for use: 1 filter pack 2.0 g or 3.0 g or 2-3 pack 1.0 g, or 2 teaspoons placer (3.0 g) pour 1 Cup (200 ml) of boiling water for 15 minutes, drain, squeeze. Adults take 1 Cup of infusion 3 times a day during meals. Course duration: 1 month. If necessary, the reception of biologically active food supplements in the form of herbal collection of sedation can be repeated.

The invention is illustrated by the following examples.

Example 1.

Dried and ground raw material, namely, the herb of oregano in the amount of 40%, herb Leonurus cardiaca in an amount of 30%, hawthorn fruit 20%, hop cones in the amount of 10% mix and Packed 2 g in filter bags.

Example 2.

Dried and ground raw material, namely, the herb of oregano in the amount of 50%, herb Leonurus cardiaca 20%, hawthorn fruit 15%, hop cones in the amount of 15% mix and pre-Packed in 3 g in filter bags.

Example 3.

Dried and ground raw material, namely, the herb of oregano in an amount of 30%, herb Leonurus cardiaca 40%, hawthorn fruit, 25%, hop cones in the amount of 5% of mix and Packed� scattering in semi-rigid packs.

The experiments illustrate the increased sedative activity of the claimed herbal collection in relation to the phytocomplex according to the Patent of Russian Federation №2150286.

This was carried out to study the effect of drugs on the duration of hexenal sleep in rats.

Animals (rats weighing 150-160 g) were divided into 3 groups.

Animals from group 1 received saline 2 ml for 1 hour prior to the introduction of hexenal.

Animals of group 2 were injected an infusion of the phytocomplex according to the invention, containing an infusion rate of 3 g collection in 200 ml of boiling water (insisted for 15 minutes). The herbal collection had the following composition: grass oregano in an amount of 30%, herb Leonurus cardiaca 40%, hawthorn fruit, 25%, hop cones in the amount of 5%. The infusion was administered into the stomach by gavage at 2 ml 1 hour before the single intraperitoneal administration of hexenal at a dose of 60 mg/kg of animal weight.

The animals of group 3 was injected with 2 ml of infusion of herbal collection prototype. This infusion prepared from 3 g collection (motherwort 30,0, hop cones 40,0, nettle leaves 30,0), which was poured to 200 ml of boiling water, was it in a water bath for 15 minutes.

It was found that in animals of the 1st group (control) duration of hexenal sleep averaged a 24.5±1.5 min In animals that were administered the phytocomplex according to the invention, prod�littlest sleep was 40.5±2,2 min, and in animals treated with the gathering of the prototype, the duration of sleep was 32.1±2,3 min.

Thus, the experimental data showed greater sedative activity when using the phytocomplex according to the claimed invention.

When you decrease the specified quantitative content of ingredients sedative activity in the form of hexenal sleep significantly decreased, therefore, we have chosen the claimed amount.

Were also conducted comparative studies to determine the sedative activity of the claimed herbal collection and herbal collection prototype on the condition of patients with asthenoneurotic syndrome and clotting of blood.

Were selected 2 groups of patients in 10 people suffering from asthenoneurotic syndrome. Women complained of fatigue, weakness, irritability, mood swings, reduced efficiency, disturbances of appetite and sleep. Some of them have heart problems: tachycardia, feeling short of breath, intolerance of transport, motion sickness, nausea, fainting. Some of the patients were observed dizziness and headaches.

All subjects were assigned pathogenetic treatment, depending on their specific diagnosis. In addition, group 1 was assigned to photonasty, according to the invention, 3 times a day 1 Cup during meals�. 2 the group was appointed by the infusion of the herbal collection, according to the prototype, in the amount of 1/3 of a Cup 30 minutes before meals. All patients before the start of the experiment was the measurement of blood clotting. It ranged from 30 to 100 seconds and averaged for group 1 80±12,0 s, and for group 2 82±10 sec.

Efficiency comparable teas were evaluated in a survey of patients, namely by the presence or time of the disappearance they have the signs above asthenoneurotic syndrome: fatigue, weakness, irritability, mood swings, decreased performance, disruption of appetite and sleep, dizziness and the presence of headaches.

As shown by the results of the study, by the end of 10 days the subjects group 1 noted improvement in sleep and mood, reducing irritability, increase efficiency, appetite and improved sleep. In patients of group 2 such improvements occurred only on day 18-25.

Coagulation time of the blood in patients of the 1st group after administration of Finasta (on day 25) was 90+12,5 s, and 2 patients of group it ranged from 10 (2 cases) up to 80 seconds and averaged 50,0+13,2 sec.

According to research the average value of the clotting time of blood when use of the herbal collection and phytocomplex according to the prior art, although it was normal, but when and�use of the phytocomplex according to the prior art it is more than 1.5 times higher than the original this is not observed in subjects receiving the claimed photonasty.

Thus, these results show increased therapeutic efficacy of the claimed herbal collection in the form of its sedative action, elimination of side effect in the form of negative effect of infusion on blood coagulation and its improved organoleptic properties as the nice aroma and taste of the infusion, the preparation of which is the herbal collection.

Known information from the scientific literature and experiments allow us to conclude that the proposed herbal collection, thanks to the optimal combination of herbal ingredients, has a sedative effect, non-toxic, has a pleasant organoleptic properties and minimal risk of side effects. Recommended as a biologically active food Supplement - a source of flavonoids, containing iridoids and essential oils.

1. The herbal collection of sedation, containing a mixture of dried and powdered herb of Leonurus cardiaca and hop cones, characterized in that it additionally contains the herb oregano and fruits of hawthorn, with the following ratio of components, wt.%:

Grass oregano 30-50
Herb Leonurus cardiaca20-40
Hawthorn10-30
Hop cones5-15

2. The phytocomplex according to claim 1, characterized in that the single dose collection for the preparation of photonasty is 1-3.

3. The phytocomplex according to claim 1, characterized in that it is packaged in filter bags 1-3 G.



 

Same patents:

FIELD: medicine, pharmaceutics.

SUBSTANCE: invention relates to pharmaceutical composition for treating insomnia. Said composition includes root of Polygonum multiflorum and/or its extracts, seeds of Ziziphus spinosa and/or its extracts, mulberry fruit and/or its extracts, Ganoderma and/or its extracts, lily bulb and/or its extracts, Anemarrhena rhizome and/or its extracts, root of Salvia miltiorrhiza and/or its extracts, chrysanthemum flower and/or its extracts, Poria and/or its extracts and Albizia flower and/or its extracts. Invention also relates to application of said composition.

EFFECT: claimed invention provides sedative and soporific effect, contributes to memory stimulation.

17 cl, 6 tbl, 14 ex

FIELD: medicine, pharmaceutics.

SUBSTANCE: invention refers to compounds of formula (I) and their pharmaceutically acceptable salts, wherein A is thiazolyl, oxazolyl, thienyl, furyl, imidazolyl, pyrazolyl or oxadiazolyl (structures of which are presented in cl.1 of the patent claim), R1 represents C1-6alkyl; R2 represents (i) phenyl substituted by halogen; C1-6alkyl optionally substituted by morpholine or C1-6dialkylamino; C1-6alkoxy optionally substituted by halogen; or heterocyclyl, wherein a heterocyclyl substitute is specified in morpholine; pyrazolyl optionally substituted by C1-6alkyl; piperidinyl; pyrrolidinyl; oxadiazolyl substituted by C1-6alkyl; furyl substituted by C1-6alkyl; dioxydoisothiazolidinyl; triazolyl; tetrazolyl substituted by C1-6alkyl, tridiazolyl substituted by C1-6alkyl; thiazolyl substituted by C1-6alkyl; pyridyl; or pyrazinyl; (ii) substituted or unsubstituted heterocyclyl specified in quinolinyl; pyridyl substituted by C1-6alkoxy or morpholinyl; or benzo [d] [1, 2, 3] triazolyl substituted by C1-6alkyl; R3 represents phenyl substituted by 2 or 3 substitutes specified in halogen; C1-6alkyl; C1-6alkoxy optionally substituted by halogen; hydroxy group; cyano; or -C(=O)ORa, wherein Ra represents phenyl; R4 represents hydrogen, C1-6alkyl or C1-6halogenalkyl. The invention also refers to a pharmaceutical composition containing the compounds of formula (I), a method for PDE10 inhibition, a method of treating neurological disorders, and to intermediate compounds: 2-(4-chlor-3,5-dimethoxyphenyl)furan and 4-(5-methyl-1,3,4-thiadiazol-2-yl)benzaldehyde.

EFFECT: compounds of formula (I) as PDE10 inhibitors.

39 cl, 13 ex, 2 tbl, 77 dwg

FIELD: medicine, pharmaceutics.

SUBSTANCE: invention refers to medicine, particularly to experimental pharmacology, and can be used as a method for rat sedation with an api-phytocomposition. The method for rat sedation with the api-phytocomposition involving single and daily one-week administration of a sedative agent, which is administered intragastrically through a probe in a dose of 200 mg/kg of animal's body weight, wherein the api-phytocomposition contains honey, bee-bread, lime pollen, propolis, valerian extract in a ratio of 10:2:1:1:1, and represents an aqueous suspension.

EFFECT: method described above is effective for rat sedation and causes no side effects.

1 ex

FIELD: medicine, pharmaceutics.

SUBSTANCE: invention refers to pharmaceutics and medicine and concerns using comenic acid potassium salt as a preventive and therapeutic antioxidant, stress- and neuroprotective agent in the amount of 2 to 8 mg per 1 kg of body weight daily on the empty stomach for 3 days.

EFFECT: agent possess high efficacy.

4 tbl

FIELD: chemistry.

SUBSTANCE: invention relates to novel pyranyl aryl methylbenzoquinazolinone compounds of formula (I), which are positive allosteric modulators of the M1 receptor and which can be used to treat diseases associated with the M1 receptor, such as Alzheimer's disease, schizophrenia, pain disorders or sleep disturbance. In formula (I) X-Y are selected from a group comprising (1) -O-CRARB-, (2) -CRARB-O-, (3) -CRARB-SRC-, (4) -CRARB-NRC- and (5) -NRC-CRARB-, where each RA and RB is a hydrogen atom, and RC is selected from a group comprising (a) hydrogen, (b) -C(=O)-C1-6alkyl, (c) -C1-6alkyl, (d) -C(=O)-CH2-C6H5, (e) -S(=O)2-C1-6 alkyl, R1 is a hydroxy group, R2 is selected from a group comprising (1) -phenyl, (2) - heteroaryl, where the phenyl or heteroaryl group R2 is optionally substituted; the rest of the values of the radicals are given in the claim.

EFFECT: obtaining novel pyranyl aryl methylbenzoquinazolinone compounds.

28 cl, 12 tbl, 37 ex

FIELD: medicine, pharmaceutics.

SUBSTANCE: invention refers to medicine and pharmacology and concerns using comenic acid sodium salt as a preventive and therapeutic antioxidant, stress and neuroprotective agent in the amount of 1 to 4 mg per 1 kg of body weight daily on the empty stomach for 3 days.

EFFECT: invention provides the high clinical effectiveness.

3 tbl

FIELD: medicine, pharmaceutics.

SUBSTANCE: invention refers to medicine, particularly to pharmacology and pharmaceutics, and concerns a sedative agent representing glycine immobilised on detonation nanodiamond particles 2-10 nm in size, and to a method for preparing it.

EFFECT: preparing the sedative agent.

4 cl, 7 dwg, 13 tbl, 4 ex

FIELD: medicine, pharmaceutics.

SUBSTANCE: invention discloses crystalline form of S-zopicone with spectrum of powder X-ray diffraction with application of Cu-Ka radiation, with characteristic peaks, expressed under conditions 20 approximately at 11.08°, approximately 12.38°, approximately 15.86°, approximately 17.88°, approximately 19.98°C and approximately 20.58°, DSC-thermogram, on which peak is observed approximately at 207.7°C, and infrared spectrum of absorption (IR) with characteristic peaks approximately at 3078 cm-1, approximately 2942-2838 cm-1, approximately 2790 cm-1, approximately 1716 cm-1, approximately 1463 cm-1, approximately 1372 cm-1 and approximately 757 cm-1.

EFFECT: claimed are: method of preparation of crystalline form of eszopiclone, pharmaceutical preparation and its application in manufacturing medication for treatment of sleep disorder.

8 cl, 8 dwg, 10 ex

FIELD: medicine.

SUBSTANCE: present group of inventions refers to medicine, namely therapy and neurology, and concerns a melatonin agonist therapy. As the above melatonin agonist, (lR-Trans)-N-[[2-(2,3-dihydro-4-benzofuranyl)cyclopropyl]methyl]propanamide is administered in effective doses that provides treating or preventing disruption of circadian rhythm or sleep disturbance.

EFFECT: invention provides treating or preventing disruption of circadian rhythm or sleep disturbance.

9 cl, 2 ex, 4 tbl

FIELD: medicine, pharmaceutics.

SUBSTANCE: present invention provides new imidazo[1,2-b]pyridazine compounds covered by general structural formula (I) wherein the radicals and symbols have the values presented in the patent claim, and pharmaceutically acceptable salts thereof. The compounds of structural formula (I) are effective both for treating or preventing the diseases related to GABA receptor inhibition, anxiety, epilepsy, sleep disorders, including insomnia, and for inducing a sedative-hypnotic, anaesthetic effect, sleep and muscle relaxation.

EFFECT: there are presented methods for preparing the above compounds, and also intermediate compounds for preparing them.

21 cl, 4 tbl, 13 ex

FIELD: medicine.

SUBSTANCE: a phytopreparation containing bee wax 1.9 g and a herbal extract 0.1 g with the above herbal extract containing common oak bark, common St. John's wort herb and creeping thyme (Thymus) herb in equal proportions is used.The preparation is used as a chewing substrate (a chewing gum) for two weeks 3 times a day 15 minutes after meals.

EFFECT: using the invention improves clinical manifestations of the disease; oral inflammations are supposed to relieve or reduce; the length of erosion and ulcer epithelisation is reduced; the oral fluid structural properties are normalised by increasing phosphorus and magnesium, reducing protein, calcium and TBA.

1 tbl, 1 ex

FIELD: medicine, pharmaceutics.

SUBSTANCE: group of inventions relates to pharmaceutical industry, namely to composition for treating skin ageing. Composition for treating signs of skin ageing, increase of cytikin IL-1α secretion, contains: NF-kB inhibitor, selected from the group, consisting of substituted resorcinols, (E)-3-(4-methylphenylsulphonyl)-2-propenenitrile, tetrahydrokurkuminoids, extracts of Paulownia tomentosa wood, as well as their combinations, and anti-inflammatory compound, which is not NF-kB inhibitor. Composition for treating signs of skin ageing, increase of cytokine IL-1α, containing NF-kB inhibitor, selected from the group, consisting of substituted resorcinols, and anti-inflammatory compound (versions).

EFFECT: compositions are effective for treating signs of skin ageing.

4 cl, 9 tbl, 9 ex

FIELD: chemistry.

SUBSTANCE: invention relates to method of obtaining 7-hydroxyroyleanon, possessing antimicrobial action. said method includes extraction of crushed roots of salvia officinalis with 96% ethyl alcohol with further extract evaporation, processing with water, alcohol distillation and processing with hydrophobic solvent or extraction of said raw material with chloroform with further extract processing with water and evaporation; after which target product is extracted from organic phase by transfer into water-soluble phenolates, with processing with sodium hydroxide water solution; alkali solution is washed with chloroform; acidified with hydrochloric or sulphuric acid; obtained sediment is filtered; dried and crushed.

EFFECT: invention is characterised by improved process manufacturability and provides obtaining individual substance with higher antimicrobial activity than previously extracted royleanon derivatives from salvia officinalis.

2 tbl, 6 ex

FIELD: chemistry.

SUBSTANCE: group of inventions relates to a process of producing organic substrate particles bonded to switchable ferromagnetic nanoparticles with a mean particle diameter ranging from 10 to 1000 nm, to the use of such nanoparticles for hyperthermic treatment of an organism and to a drug for the hyperthermc treatment. As the ferromagnetic nanoparticles used are nanoparticles, which are non-ferromagnetic at first, but become ferromagnetic when the temperature is lowered, these initially non-ferromagnetic dispersed nanoparticles are bonded to the organic substrate particles, and then the nanoparticles bonded to the substrate particles become ferromagnetic as a result of the temperature decrease, initially the switchable ferromagnetic nanoparticles at the temperature of 22°C or higher are not ferromagnetic and become ferromagnetic as a result of cooling down to the temperatures below 22°C. The switchable ferromagnetic nanoparticle comprises Mn and additionally Fe and/or As and preferably have the Fe2P-structure or Na-Zn-13-structure, alternatively, or may comprise La, Fe and Si.

EFFECT: invention prevents the agglomeration of particles and an increase in the mean particle size.

10 cl, 1 dwg, 2 ex

FIELD: medicine.

SUBSTANCE: using dense extract of cowslip primrose (Primula veris L.) herb as a hepatoprotective agent.

EFFECT: agent is effective as a hepatoprotector.

1 tbl

FIELD: chemistry.

SUBSTANCE: invention represents method of obtaining thermosensitive iodine-containing radiopharmaceutical (RP) with radiochemical purity 95-98%, consisting in covalent binding of radioactive iodine isotopes to tyrosine groups, included into chain of poly-N-isopropylacrylamide, with further separation of labelled polymer component from low molecular compounds on chromatographic gel column by elution with water, characterised by the fact that as mobile phase used are water solutions of chemical compounds, mainly inorganic salts, possessing coefficient of polymer-hydrate-iodine complex γ=dTftdCs destabilisation from the interval γ=30-60 degree·l/mol, where Tft is temperature of phase transition in solution, containing destabilising additive, Cs is concentration of additive, limited from above by condition γCs<Tft0Tк (Tft0=Tft, at Cs=0, Tc is temperature in column).

EFFECT: creation of RP with high radiochemical frequency and reduction of radioactive pollution of the environment.

6 dwg, 2 tbl, 9 ex

FIELD: medicine.

SUBSTANCE: 20-25 minutes after surgical intervention, a mouth bath of an implantation area with the Tonsinal phytopreparation diluted in an amount of 2.5 g in 100 ml of boiled water of room temperature is executed. 20-25 minutes later the Plastin CM-1 phytopreparation is applied on the alveolar process mucosa within the implantation area from the vestibular side for 1.5-2 hours. That is preceded by the desalivation of the oral cavity and mouth rinsing carefully with the Tonsinal solution trying to avoid any dynamic movements. The above procedures are performed 3-4 times a day for at least 10 days.

EFFECT: more effective dental implantation by improving microcirculation, fast normalising of oral microbiocoenosis, wound surface healing by immediate union, reliable implant attachment to gums and providing the implant stability.

3 ex

FIELD: medicine.

SUBSTANCE: ointment contains wax 13-15 wt %, glycerol 15-20 % and vegetable oil; the prepared ointment mass is exposed to ozone for 15-20 min in a yield amount of 10 mg/l.

EFFECT: invention provides the advanced healing efficacy with no side effects by reducing the time of wound cleansing from purulo-necrotic tissues.

3 ex

FIELD: medicine, pharmaceutics.

SUBSTANCE: invention refers to the pharmaceutical industry, particularly to a composition for treating asthenic syndrome in patients with dyscirculatory encephalopathy. An ester-oil composition for treating asthenic syndrome in the patients with dyscirculatory encephalopathy contains eucalyptus, mint, pine, cedar, lavender, carnation, flax essences taken in certain relations.

EFFECT: composition is effective for treating asthenic syndrome in the patients with dyscirculatory encephalopathy; it causes the selective harmonising action on the central nervous system, regulates the emotional status, improves cognitive functions, reduces clinical manifestations of asthenic syndrome considerably and improves the quality of life in the patients with dyscirculatory encephalopathy.

1 tbl, 1 ex

FIELD: medicine.

SUBSTANCE: invention relates to medicine, namely to dentistry, therapeutic-prophylactic preparation for tooth and oral cavity care, and can be applied for prevention and complex treatment of inflammatory diseases of gums, parodentium, stomatitis or elimination of gingival hemorrhage. Therapeutic-prophylactic toothpaste includes glycerin, laurylglycoside, sorbitol, xylite, aerosol, calcium hydrogen phosphate, xanthane resin, sodium benzoate, CO2-extracts of thyme, sage, rosemary, white clay, green clay, red clay and water with specified content of components. For CO2-extracts of thyme, sage and rosemary fulfilled is ratio Wt/Ws/Wr=(0.40-0.50)/(0.25-0.35)/0.20-0.25), where Wt, Ws, Wr are weight parts of respectively CO2-extracts of thyme, sage and rosemary, with particles of green, white and red loam having sizes in interval 0.1-100 mcm and being obtained from clay, dried at 80-400°C.

EFFECT: technical result consists in increased efficiency of prevention and treatment of inflammatory diseases of oral cavity, parodentium, in particular gingivitis, periodontitis, as well as increase of cleaning ability of toothpaste with simultaneous reduction of abrasive influence on tooth enamel; and technical result consists in extension of arsenal or toothpastes of complex action, which render healing and preventive action on organs and tissues of oral cavity.

9 cl

FIELD: medicine, oncology, amino acids.

SUBSTANCE: invention relates, in particular, to the development of an antitumor preparation based on natural substances. Invention relates to an amino acid preparation comprising at least one modified essential amino acid obtained by treatment of amino acid by ultraviolet radiation (UV) at wavelength 250-350 nm for 12-80 h at temperature 15-30oC or with ozone at temperature 15-25oC. The modified amino acid has no toxicity for health cells. Also, invention relates to a method for preparing such preparation. Invention provides the development of an antitumor preparation based on modified amino acids and expanded assortment of antitumor preparations being without cytotoxicity for normal cells.

EFFECT: valuable medicinal antitumor properties of preparation.

8 cl, 4 tbl, 2 dwg, 4 ex

Up!